Kyverna Therapeutics (KYTX) Non-Current Assets (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Non-Current Assets data on file, last reported at $15.3 million in Q1 2026.

• Quarterly Non-Current Assets rose 17.64% year-over-year to $15.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.6 million (down 8.3% YoY) and the FY2025 annual result came in at $10.9 million, down 22.58% from the prior year.
• Non-Current Assets grew to $15.3 million in Q1 2026, from $10.9 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $15.3 million in Q1 2026 to a low of $10.9 million in Q4 2025.
• A 4-year average of $13.5 million and a median of $13.9 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2025 — Non-Current Assets fell 22.58% — and 2026, when it gained 17.64%.
• Tracing KYTX's Non-Current Assets over 4 years: stood at $14.5 million in 2023, then dropped by 3.35% to $14.0 million in 2024, then retreated by 22.58% to $10.9 million in 2025, then jumped by 40.7% to $15.3 million in 2026.
• The last three Non-Current Assets figures came in at $15.3 million (Q1 2026), $10.9 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.